First Cohort Benefits From Atsena Therapeutics XLRS Gene Therapy
UF startup Atsena Therapeutics has announced positive preliminary data for its gene therapy candidate ATSN-201 for the treatment of X-linked retinoschisis (XLRS).
Atsena Therapeutics Announces Positive 12-Month Safety and Efficacy Data From Ongoing Phase I/II Clinical Trial To Treat Leber Congenital Amaurosis
Atsena Therapeutics announced positive results in their 12-month safety and efficacy data from the ongoing Phase I/II trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 has conferred clinically meaningful improvements in vision at the highest dose with no serious treatment-emergent adverse events.
Atsena Therapeutics Unveils XLRS Gene Therapy Program Leveraging Novel Spreading Capsids
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, unveiled its preclinical gene therapy program for X-linked retinoschisis (XLRS), a monogenic disease caused by mutations in the RS1 gene.
Atsena Therapeutics Appoints Linda B. Couto, Ph.D., as Chief Scientific Officer
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced the appointment of Linda B. Couto, Ph.D., as Chief Scientific Officer (CSO).
Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced the appointment of Jennifer Wellman to its board of directors.
Atsena Therapeutics Receives Orphan Drug Designation From the FDA for Novel Gene Therapy To Treat Genetic Eye Disease LCA1
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for its investigational gene therapy product for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1), a genetic eye disease that affects the retina.
Atsena Therapeutics Appoints Kenji Fujita, MD, as Chief Medical Officer
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced the appointment of Kenji Fujita, MD, to the newly created position of Chief Medical Officer.
Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, announced it has closed an oversubscribed $55 million Series A financing led by Sofinnova Investments with participation from additional new investors Abingworth and Lightstone Ventures.
Atsena Therapeutics Acquires Exclusive Rights to Gene Therapy for GUCY2D-Associated Leber Congenital Amaurosis
UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent... Read More
